Federal judge pauses case on mifepristone access until after midterm elections
If Florida and Texas win their lawsuit citing the 150-year-old Comstock Act, mifepristone could become unavailable nationwide regardless of state abortion laws.

Type at least 2 characters to search.

Kelcie Moseley-Morris covers reproductive rights for Stateline. Based in Idaho, she has covered the effects of abortion bans nationwide, as well as reproductive health issues.
If Florida and Texas win their lawsuit citing the 150-year-old Comstock Act, mifepristone could become unavailable nationwide regardless of state abortion laws.

Idaho's attorney general is appealing the ruling, while legal experts say the case could reach the Supreme Court and test Dobbs over mental health exceptions.

An Idaho lawmaker who used both IVF and surrogacy to build her family says surrogacy restrictions are likely coming to her state's 2027 legislative session.

The Pence-founded group wants the 1873 Comstock Act enforced to stop mailed pills, which accounted for 27% of abortions nationwide in early 2025.

The Virginia ruling echoes a Hawaii decision and comes as separate lawsuits from Louisiana to Texas seek to restrict or revoke mifepristone entirely.

The overhaul cancels evidence-based programs serving 1,200 NYC teens and could open funding to anti-abortion crisis pregnancy centers, critics say.

The rule would let agencies cancel grants without notice for political reasons, threatening maternal health programs amid 278,000 public comments before an Oct. 1 deadline.

HHS canceled $68 million in teen pregnancy prevention grants two years early, citing misalignment with agency priorities—a move that prompted legal action during Trump's first term.

The 5th Circuit temporarily blocked the FDA rule in May, but the Supreme Court paused that decision while the case proceeds—and the rule could still fall.

Abortion funds say fuel prices and inflation are forcing some to temporarily close as demand has more than doubled since the Dobbs decision.

Doctors in states with abortion bans are avoiding the most effective two-drug miscarriage treatment, citing legal fears, forcing patients toward less reliable options.

The decision preserves access while Louisiana's lawsuit continues, but anti-abortion groups are pressuring Trump's new FDA commissioner to block the drug.

Get local news and stories delivered to your inbox.
newsbriefing@tiffinohio.net to your contacts to ensure our newsletters reach your inbox.Free reader account
Get a personalized For You feed, save stories for later, track your reading history, and more features coming soon.
We'll email you a one-time sign-in link — no password needed.
Check your email
We sent a magic link to . Click it to finish creating your account.